Danielle Bucco

Articles

Novel Immunotherapy Approaches Moving Through RCC Pipeline

October 12th 2017

Matthew R. Zibelman, MD, discussed the promise of immunotherapy combinations for patients with kidney cancer.

Expert Shares Insight on Developments in T-Cell Lymphoma

October 12th 2017

Jonathan Brammer, MD, discusses exciting therapeutic developments for patients with T-cell lymphoma.

Expert Urges for a More Multidisciplinary Approach to Bladder Cancer Care

October 6th 2017

Robert Jones, MD, discusses the future treatment landscape for patients with urothelial carcinoma in a more multidisciplinary setting.

Exploring the Role of Chemotherapy and Immunotherapy Combos in Urothelial Carcinoma

October 5th 2017

Andrea Necchi, MD, discusses the current role of immunotherapy and chemotherapy for patients with muscle-invasive bladder cancer.

Novel Imaging Techniques Advancing Prostate Cancer Care

October 5th 2017

William R. Berry, MD, discusses luteinizing hormone-releasing hormone agonists versus antagonists as treatment options for patients and highlights the novel techniques for prostate cancer imaging.

Advanced RCC Results Point to Potentially New Frontline Treatments

October 5th 2017

Michael R. Harrison, MD, discusses emerging data that are likely to impact the treatment landscape for patients with RCC.

Phase III Data Show Benefit With Abiraterone in Castration-Sensitive Prostate Cancer

October 4th 2017

Tian Zhang, MD, discusses emerging results for patients with metastatic castration-sensitive prostate cancer.

Emerging Data Show Promise With Immunotherapy Combos in NSCLC

October 3rd 2017

Jyoti D. Patel, MD, discusses ongoing research investigating immunotherapy in combination with chemotherapy for patients with NSCLC.

Expert Discusses Ongoing Advances With Immunotherapy in CRC

September 28th 2017

Tanios Bekaii-Saab, MD, discusses the emerging role of immunotherapy in patients with MSI-H colorectal cancer.

Grothey Highlights Biomarker Research in CRC

September 26th 2017

Axel Grothey, MD, discusses current first-line treatments for patients with CRC and the importance of developing biomarkers for this population.

Therapies in Development to Improve Outcomes in BRAF-Mutated CRC

September 26th 2017

Tim G. Larson, MD, discusses emerging data involving immunotherapy for patients with microsatellite instability (MSI)/microsatellite stable (MSS) colorectal cancer (CRC) and highlighted some of the identified molecular mutations in patients with CRC

Therapeutic Advancements Changing Liver Cancer Paradigm

September 26th 2017

Steven R. Alberts, MD, discusses current advancements being made for patients with advanced liver cancer.

Use of Active Surveillance Increasing for Low-Risk Prostate Cancer

September 21st 2017

Matthew R. Cooperberg, MD, discusses the benefits associated with active surveillance for patients with low-risk prostate cancer, as well as the development of personalized medicine.

Burtness Discusses Next Steps With Immunotherapy in Head and Neck Cancer

September 19th 2017

Barbara A. Burtness, MD, discusses the current role of immunotherapy in head and neck cancer and potential combination regimens on the horizon.

Expert Highlights Immunotherapy Potential in Ovarian Cancer

September 19th 2017

Dmitriy Zamarin, MD, PhD, discusses immunotherapy for patients with ovarian cancer.

Expert Discusses Approval of First CAR T-Cell Therapy

September 18th 2017

James L. Ferrara, MD, discusses the significance of the FDA approving tisagenlecleucel as the first CAR T-cell therapy.

Biomarkers Needed for Premenopausal Women With Breast Cancer

September 17th 2017

Ongoing studies are hoping to find a biomarker to guide which premenopausal women with ER-positive breast cancer need extended adjuvant therapy and which need ovarian function suppression.

Lenvatinib Continues to Show Noninferiority to Sorafenib in Liver Cancer

September 17th 2017

First-line therapy with lenvatinib continued to be noninferior in overall survival and achieve significant improvements in progression-free survival, time to progression, and objective response rate compared with sorafenib for patients with unresectable hepatocellular carcinoma.

Implementation Research Key to Solving Global Cancer Care Puzzle

September 16th 2017

Health investment is failing to match the challenge presented by a growing cancer burden in countries at all economic levels, enhancing the need for new approaches that help optimize the delivery of care.

STORM Study Fails to Find Predictive Biomarkers for Sorafenib in HCC

September 16th 2017

Hepatocyte pERK-positive immunostaining and microvascular invasion were independent prognostic factors of recurrence-free survival for patients with hepatocellular carcinoma treated with adjuvant sorafenib; however, a predictive biomarker for recurrence was not uncovered.